8 completed, 3 unknown, 2 terminated, 1 recruiting. 15 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 8, Unknown 3, Terminated 2, Recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow Etoricoxib: new trials by email Literature Review of Etoricoxib trials Research Report on Etoricoxib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Etoricoxib in Patients With Parkinsonian Disease L-dopa, Etoricoxib - Parkinson Disease | Phase 2 | Recruiting | Ihab Elsayed Hassan | 60 | 2026-01-30 | 2026-04-08 |
| Oral Huzhang Granules for Acute Gouty Arthritis Huzhang granule, Etoricoxib, Huzhang granule Placebo - Gouty Arthritis | Phase 2 | Unknown | Shanghai Yueyang Integrated Medicine Hospital | 267 | 2020-07-01 | 2020-07-08 |
| Prevention of Taxane-associated Acute Pain Syndrome With Etoricoxib Etoricoxib - Pain Syndrome | Phase 2 | Completed | Guangdong Provincial People's Hospital | 144 | 2020-03-01 | 2022-02-14 |
| The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168) Etoricoxib 75 mg 4% DMSO Gel, Etoricoxib 75 mg 4% PG Gel, Etoricoxib 150 mg 4% DMSO Gel - Osteoarthritis Pain | Phase 1 / Phase 2 | Completed | Organon and Co | 70 | 2013-12-23 | 2024-06-27 |
| A Single Center 2-way Crossover Study to Investigate the Mechanism of Action of Etoricoxib in Subjects With Osteoarthritis Knee Pain Etoricoxib, followed by placebo (matching tablet, without active ingredient), Placebo (matching tablet, without active ingredient), followed by etoricoxib - Osteoarthritis | Phase 2 | Completed | C4Pain | 39 | 2012-07-01 | 2013-07-23 |
| Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus - Advanced Melanoma | Phase 1 / Phase 2 | Unknown | University of Regensburg | 136 | 2012-05-01 | 2012-06-07 |
| Efficacy Study of Pre-emptive Etoricoxib for Postoperative Pain and Functional Outcome in Total Knee Arthroplasty Control, Etoricoxib - Knee Osteoarthritis | Phase 2 | Completed | Singapore General Hospital | 65 | 2011-07-01 | 2017-02-10 |
| Efficacy of Etoricoxib on Peripheral Hyperalgesia Etoricoxib, placebo - Causalgia, Polyneuropathy | Phase 2 | Terminated | Ruhr University of Bochum | 9 | 2011-02-01 | 2012-08-24 |
| Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients Etoricoxib - HIV | Phase 2 | Completed | Dag Kvale | 60 | 2010-10-01 | 2017-05-31 |
| Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis TNF alpha, NSAIDs and sulfasalazine - Ankylosing Spondylitis | Phase 2 | Unknown | Chung Shan Medical University | 300 | 2009-11-01 | 2015-05-28 |
| Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer imatinib mesylate, Treosulfane, etoricoxib - Prostate Cancer | Phase 2 | Completed | Novartis Pharmaceuticals | 67 | 2007-02-01 | 2016-11-21 |
| Modulation of the Surgical Inflammatory Response by Etoricoxib Etoricoxib 60 mg, Placebo for Etoricoxib 60 mg - Pain, Osteoarthritis, Hip | Phase 2 | Terminated | University of Erlangen-Nürnberg Medical School | 23 | 2006-05-01 | 2020-12-14 |
| Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED) etoricoxib, Comparator: placebo, Comparator: diclofenac - Rheumatoid Arthritis | Phase 2 | Completed | Organon and Co | 761 | 2006-01-01 | 2022-02-09 |
| Safety and Efficacy of an Investigational Drug Versus Placebo in the Treatment of Cancer Pain (0663-083) MK0663, etoricoxib / Duration of Treatment: 4 weeks - Bone Neoplasms | Phase 2 | Withdrawn | Organon and Co | 2004-11-01 | 2022-02-16 | |
| Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007) MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks), Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks - Osteoarthritis | Phase 2 | Completed | Organon and Co | 1167 | 1998-06-01 | 2022-02-18 |
Osteoarthritis (3) · Arthritis, Gouty (1) · Arthritis, Rheumatoid (1) · Bone Neoplasms (1) · Breast Neoplasms (1) · Causalgia (1) · Neuralgia, Postherpetic (1) · Osteoarthritis, Hip (1) · Osteoarthritis, Knee (1) · Pain (1) · Pain, Postoperative (1) · Parkinson Disease (1) · Peripheral Nerve Injuries (1) · Peripheral Nervous System Diseases (1) · Polyneuropathies (1)
Organon and Co (4) · C4Pain (1) · Chung Shan Medical University (1) · Dag Kvale (1) · Guangdong Provincial People's Hospital (1) · Ihab Elsayed Hassan (1) · Novartis Pharmaceuticals (1) · Ruhr University of Bochum (1) · Shanghai Yueyang Integrated Medicine Hospital (1) · Singapore General Hospital (1) · University of Erlangen-Nürnberg Medical School (1) · University of Regensburg (1)
Germany (4) · China (1) · Denmark (1) · Egypt (1) · Norway (1) · Singapore (1) · Taiwan (1)
Albrecht Reichle, Professor (1) · Asokumar Buvanendran, MD (1) · Christoph Maier, Dr.med (1) · Dag Kvale, MD, PhD (1) · Hans Christian Hoeck, MD PhD (1) · Jia Zhou (1) · Josef Zacher, MD, PhD (1) · Kay Brune, MD, PhD (1) · Kun Wang, MD (1) · Martin Fromm, MD, PhD (1) · Shi-lu Chia, MBBS (1) · Wei C- C, M.D. (1)
PMID 16321158, PMID 20052461, PMID 21905970, PMID 22337568, PMID 25886874, PMID 28464042, PMID 35365187, PMID 35724467
2009 (1)